データ制約下での薬剤レベル炭素フットプリント評価のためのハイブリッドLCA枠組み：狭域ペニシリンへの適用
A Hybrid LCA Framework for Drug-Level Carbon Footprint Assessment under Data Constraints: Application to Narrower-Spectrum Penicillin (原題)
Rick Hagenaars, Arjan de Koning, Reinout Heijungs, Arnold Tukker, Ranran Wang
🤖 gxceed AI 要約
日本語
医薬品の炭素フットプリントは国ごとに大きく異なるが、薬剤レベルのデータ不足で推定が困難である。本論文は、薬剤レベルのライフサイクルインベントリと国際貿易統計を組み合わせ、不確実性評価を組み込んだハイブリッドLCA枠組みを開発した。狭域ペニシリンの2019年の世界消費は約90kt CO2eと推定され、地理的分布は医薬品全体と大きく異なることを示した。この枠組みは、データ不足下での薬剤レベル炭素会計の透明な経路を提供する。
English
Drug-level carbon footprints vary significantly across countries, but data scarcity hinders estimation. This paper develops a hybrid LCA framework combining drug-level inventories with international trade statistics and uncertainty assessment. Applying it to narrower-spectrum penicillin, global consumption in 2019 was ~90 kt CO2e, with geographic distribution differing markedly from aggregated pharmaceuticals. The framework offers a transparent pathway for drug-level carbon accounting under data constraints.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本では、サステナビリティ情報開示の義務化が進み、医薬品業界でもScope3排出量の算定が求められる可能性がある。本枠組みは、データ不足下での薬剤レベル炭素会計を可能にし、調達や製品ポートフォリオの脱炭素化に貢献する。
In the global GX context
Globally, initiatives like digital product passports and CSRD are pushing for product-level carbon reporting. This framework addresses data scarcity in pharmaceuticals, enabling more accurate Scope 3 accounting and supporting procurement decisions. It highlights cross-country heterogeneity that sector-level accounting masks, informing policy and corporate strategy.
👥 読者別の含意
🔬研究者:Provides a methodological framework for product-level carbon accounting under data constraints, with uncertainty assessment.
🏢実務担当者:Enables pharmaceutical companies to estimate drug-specific carbon footprints for reporting and procurement.
🏛政策担当者:Informs policies on product-level carbon reporting and digital product passports.
📄 Abstract（原文）
Abstract Understanding differences in drug-specific carbon footprints across countries is increasingly important as healthcare sustainability and product-level reporting gain prominence in regulatory initiatives, such as digital product passports, yet such estimates remain largely unavailable due to sparse drug-level data. Here, we develop a hybrid life cycle assessment framework that enables quantification of drug-specific carbon footprints across regions under real-world data constraints. It combines drug-level life cycle inventory with international consumption and trade statistics and embeds a structured uncertainty assessment to evaluate key data gaps and modeling choices through robustness tests. We demonstrate its application using narrower-spectrum penicillin. We estimate that its global consumption in 2019 was associated with about 90 kt CO2e. Although modest in magnitude, the footprint’s geographic distribution differs markedly from that of aggregated pharmaceuticals, showing that sector-level accounting can mask substantial cross-country heterogeneity. Across alternative assumptions, global totals vary by less than 30%, and country rankings remain largely stable, indicating that the observed patterns reflect structural differences in consumption and sourcing rather than artifacts of specific modeling choices. This framework offers a transparent pathway for drug-level carbon accounting under data scarcity and identifies data and methodological priorities to support future reporting, procurement, and decarbonization efforts in the pharmaceutical sector.
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.1021/acs.est.6c00661first seen 2026-08-22 05:04:37
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。